Product Description
Ritonavir
CAS 155213-67-5
Ritonavir is an antiretroviral protease inhibitor that is widely used in combination with other protease inhibitors in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS).
Lopinavir/Ritonavir
AI Product Description
*The following content is generated by AI and is for reference only.
Ritonavir, chemically known as (2S)-1-{(3S,5S,8R,9R,10S,11S,13S,14S,17R)-6-fluoro-17-(2-methylpropan-2-yl)-10,13-dimethyl-17-(2-methylpropyl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl}-N-[2-(methylsulfonyl)ethyl]-2-oxoethanamine, is a potent antiretroviral medication belonging to the class of protease inhibitors. Its molecular formula is C37H48N4O5S2, and it carries the unique CAS registry number 155213-67-5. Originally developed in the late 1990s by Abbott Laboratories, Ritonavir was one of the first drugs to revolutionize the treatment of Human Immunodeficiency Virus (HIV) infection, significantly reducing mortality rates globally when used in combination therapies.
The primary clinical utility of Ritonavir lies in its dual role within modern HIV management protocols. While it possesses intrinsic antiviral activity by inhibiting the HIV-1 protease enzyme, thereby preventing the maturation of viral particles, its most critical function today is pharmacokinetic boosting. Ritonavir acts as a potent inhibitor of cytochrome P450 3A4 (CYP3A4), the major hepatic enzyme responsible for metabolizing many other protease inhibitors. By co-administering low doses of Ritonavir with drugs like lopinavir, darunavir, or nelfinavir, clinicians can drastically increase the plasma concentrations and half-lives of these companion medications. This "boosting" effect allows for less frequent dosing schedules and improved therapeutic efficacy, ensuring that drug levels remain above the minimum inhibitory concentration throughout the day.
Beyond its established use in HIV therapy, research continues to explore potential applications in treating other viral infections, including Hepatitis C and certain coronaviruses, although clinical outcomes vary. Common side effects include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, along with metabolic changes like hyperlipidemia. Despite challenges regarding pill burden and drug interactions, Ritonavir remains a cornerstone in the arsenal against HIV/AIDS, demonstrating how understanding enzymatic pathways can transform a single agent into a powerful strategic tool for optimizing complex drug regimens. Its enduring presence in global health guidelines underscores its vital contribution to turning a fatal diagnosis into a manageable chronic condition.